Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology.
Targeted Therapies for Pancreatic Cancer: Overview of Current Treatments and New Opportunities for Personalized Oncology.
复制标题
DOI：
10.3390/cancers13040799
复制
发表时间：
2021-02-14
期刊：
影响因子：
5.2
通讯作者：
Konstantinidou G
中科院分区：
文献类型：
--
作者：
Leroux C;Konstantinidou G
缺乏早期诊断和缺乏合适的生物标志物，加上对现有治疗方案的耐药性，使胰腺癌成为最致命的癌症类型之一。因此，需要开发新的治疗方法，考虑到胰腺肿瘤的遗传和分子特征。在这里，我们批判性地回顾了过去和目前的努力，导致开发有效和特异性的抗肿瘤化合物，如果在适当的联合治疗中使用，可能会改变这种顽固的癌症类型成为一个可管理的。细胞毒性化疗仍然是大多数胰腺导管腺癌患者的唯一治疗选择。目前，晚期疾病患者的中位总生存期很少超过1年。由免疫细胞、内皮细胞和癌症相关成纤维细胞组成的胰腺癌的复杂网络赋予肿瘤内和肿瘤间异质性以不同的增殖和转移倾向。这种异质性可以解释为什么肿瘤的行为不一致，并且能够逃避治疗。全基因组测序技术的进步现在已经提供了识别给定癌症中的每一个体细胞突变、拷贝数变化和结构变异的可能性，从而产生了个性化的靶向治疗。在这篇综述中，我们对胰腺癌的当前和新兴治疗策略进行了概述。通过强调胰腺导管腺癌治疗的新范例，我们希望激发旨在改善患者结局的临床试验的新思路。
The lack of early diagnosis and the absence of suitable biomarkers coupled with resistance to available therapeutic options render pancreatic cancer one of the deadliest cancer types. Therefore, new therapeutic approaches are needed to be developed, taking into account the genetic and molecular profile of pancreatic tumors. Here, we critically review past and current efforts that have resulted in the development of potent and specific antitumor compounds that, if employed in the appropriate combination therapy, may change this recalcitrant cancer type into a manageable one. Cytotoxic chemotherapy remains the only treatment option for most pancreatic ductal adenocarcinoma patients. Currently, the median overall survival of patients with advanced disease rarely exceeds 1 year. The complex network of pancreatic cancer composed of immune cells, endothelial cells, and cancer-associated fibroblasts confers intratumoral and intertumoral heterogeneity with distinct proliferative and metastatic propensity. This heterogeneity can explain why tumors do not behave uniformly and are able to escape therapy. The advance in technology of whole-genome sequencing has now provided the possibility of identifying every somatic mutation, copy-number change, and structural variant in a given cancer, giving rise to personalized targeted therapies. In this review, we provide an overview of the current and emerging treatment strategies in pancreatic cancer. By highlighting new paradigms in pancreatic ductal adenocarcinoma treatment, we hope to stimulate new thoughts for clinical trials aimed at improving patient outcomes.
登录
查看更多内容
影响因子：
8.8
作者：
通讯作者：
--
DOI：
10.1016/j.radonc.2016.04.013
发表时间：
2016-05
期刊：
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
影响因子：
--
作者：
Chan E;Arlinghaus LR;Cardin DB;Goff L;Berlin JD;Parikh A;Abramson RG;Yankeelov TE;Hiebert S;Merchant N;Bhaskara S;Chakravarthy AB
通讯作者：
Chakravarthy AB
影响因子：
28.2
作者：
Aarts, Marieke;Sharpe, Rachel;Turner, Nicholas C.
通讯作者：
Turner, Nicholas C.
影响因子：
4.3
作者：
Aung W;Tsuji AB;Sudo H;Sugyo A;Ukai Y;Kouda K;Kurosawa Y;Furukawa T;Saga T;Higashi T
通讯作者：
Higashi T
影响因子：
11.5
作者：
Bedard, Philippe L.;Tabernero, Josep;Sessa, Cristiana
通讯作者：
Sessa, Cristiana